Hugh Gannon

Hugh Gannon is an accomplished scientist with extensive experience in genotoxicity and oncology research. Currently serving as Associate Director at KSQ Therapeutics, Inc. since March 2018, Gannon has contributed to IND submissions and overseen genotoxicity data packages for various therapies. Previous roles include Principal Scientist and Associate Principal Scientist at the same company, where responsibilities included developing assays and conducting CRISPR screens. Prior to this, Gannon was a Postdoctoral Research Fellow at Dana-Farber Cancer Institute, focusing on genetic dependencies in cancer, and earned a Ph.D. in Cell/Cellular and Molecular Biology from UMass Chan Medical School. Gannon's academic foundation includes a B.S. in Human Physiology from Boston University and experience in volunteer research positions exploring gene expression in cancer and viral genome sequencing.